guest ::
| Home > Publications Database > The influence of age, gender and pharmacogenetic profiles on the perspective on medicines in the German EMPAR study |
| Home > Publications Database > The influence of age, gender and pharmacogenetic profiles on the perspective on medicines in the German EMPAR study |
| Journal Article | DZNE-2024-01219 |
; ; ; ; ; ; ;
2024
PLOS
San Francisco, California, US
This record in other databases: 
Please use a persistent id in citations: doi:10.1371/journal.pone.0311267
Abstract: Pharmacogenetic testing in routine care could provide benefits for patients, doctors and statutory health insurances. Therefore, the aim of the retrospective, observational study Einfluss metabolischer Profile auf die Arzneimitteltherapiesicherheit in der Routineversorgung (EMPAR) was to analyze the relationship between pharmacogenetic profiles, the risk of adverse drug reactions, and patients' perceptions of drug therapy in 10748 adult (≥18 years) participants in Germany.A questionnaire was used to assess views and beliefs about medicines and participants individual perception of sensitivity to drug therapies. The questionnaire consisted of the Beliefs about Medicines Questionnaire (BMQ)-General scales (Overuse, Harm, Benefit), the Perceived Sensitivity to Medicines (PSM), Natural Remedy, and Gene Testing scales. The influence of gender, age, study collective, genotype and phenotype of relevant pharmacogenes on participant's perception were evaluated.Overuse, PSM and Benefit scores were significantly higher among patients of the collective International Classification of Diseases and Health Related Disorders (ICD)-10 Y57.9! diagnosis, which indicates complications related to drugs, compared to the anticoagulant/antiplatelet and cholesterol-lowering drug collective. Age and gender also played a significant role in patients' perceptions, with younger patients and female participants more likely to believe in medication overuse according to the Overuse scale score compared to older and male participants. Female participants compared to male participants and the old age group compared to the young and/or middle-age subgroup, scored higher in PSM and/or Harm scales, respectively. Only a tendency of increased Harm, Overuse and PSM scores was observed in the participant group with five or more relevant actionable variants compared to subgroups with 0 up to 4 variants.In conclusion, patients' beliefs about medicines and their drug sensitivity perceptions are influenced by various factors including age, gender, previous complications with medicines, and with some tendency also pharmacogenetic profiles. The higher association with more negative views related to treatment indicates that there is a need to target the underlying issues in affected patient groups in order to improve compliance to treatment and outcomes in routine care. Trial registration: EMPAR was registered in the German Clinical Trials Register (DRKS) on 06 July 2018 (DRKS00013909).
Keyword(s): Humans (MeSH) ; Male (MeSH) ; Female (MeSH) ; Germany (MeSH) ; Middle Aged (MeSH) ; Adult (MeSH) ; Aged (MeSH) ; Sex Factors (MeSH) ; Surveys and Questionnaires (MeSH) ; Age Factors (MeSH) ; Pharmacogenetics (MeSH) ; Drug-Related Side Effects and Adverse Reactions (MeSH) ; Retrospective Studies (MeSH) ; Young Adult (MeSH) ; Adolescent (MeSH) ; Aged, 80 and over (MeSH)
; 
; 
; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection ; Zoological Record
|
The record appears in these collections: |
PDF
PDF (PDFA)